# A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

> **NCT07280013** · PHASE1 · RECRUITING · sponsor: **C4 Therapeutics, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** Cemsidomide
- **BIOLOGICAL:** Elranatamab

## Key facts

- **NCT ID:** NCT07280013
- **Lead sponsor:** C4 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280013, "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07280013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*